Cargando…

Validity of sample sizes in publications of randomised controlled trials on the treatment of age-related macular degeneration: cross-sectional evaluation

OBJECTIVE: The aim of this cross-sectional study was to examine the completeness and accuracy of the reporting of sample size calculations in randomised controlled trial (RCT) publications on the treatment of age-related macular degeneration (AMD). METHODS: A sample of 97 RCTs published between 2004...

Descripción completa

Detalles Bibliográficos
Autores principales: Tulka, Sabrina, Geis, Berit, Baulig, Christine, Knippschild, Stephanie, Krummenauer, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797239/
https://www.ncbi.nlm.nih.gov/pubmed/31601589
http://dx.doi.org/10.1136/bmjopen-2019-030312
_version_ 1783459776702709760
author Tulka, Sabrina
Geis, Berit
Baulig, Christine
Knippschild, Stephanie
Krummenauer, Frank
author_facet Tulka, Sabrina
Geis, Berit
Baulig, Christine
Knippschild, Stephanie
Krummenauer, Frank
author_sort Tulka, Sabrina
collection PubMed
description OBJECTIVE: The aim of this cross-sectional study was to examine the completeness and accuracy of the reporting of sample size calculations in randomised controlled trial (RCT) publications on the treatment of age-related macular degeneration (AMD). METHODS: A sample of 97 RCTs published between 2004 and 2014 was reviewed for the calculation of their sample size. It was examined whether a (complete) description of the sample size calculation was presented. Furthermore, the sample size was recalculated, whenever possible based on the published details, in order to verify the reported number of patients. PRIMARY OUTCOME MEASURE: The primary endpoint of this cross-sectional investigation was a described sample size calculation that was reproducible, complete and correct (maximum tolerated deviation between reported and replicated sample size ±2 participants per trial arm). RESULTS: A total of 50 publications (52%) did not provide any information on the justification of the number of patients included. Only 17 publications (18%) provided all the necessary parameters for recalculation; 8 of 97 (8%, 95%-CI: 4% to 16%) publications achieved the primary endpoint. The median relative deviation between reported and recalculated sample sizes was 1%, with a range from −43% to +66%. CONCLUSION: Although a transparent sample size legitimation is a crucial determinant of an RCT’s methodological validity, more than half of the RCT publications considered failed to report them. Furthermore, reported sample size legitimations were often incomplete or incorrect. In summary, clinical authors should pay more attention to the transparent reporting of sample size calculation, and clinical journal reviewers may opt to reproduce reported sample size calculations. SYNOPSIS: More than half of the analysed RCT publications on the treatment of AMD did not report a transparent sample size calculation. Only 8% reported a complete and correct sample size calculation.
format Online
Article
Text
id pubmed-6797239
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-67972392019-10-31 Validity of sample sizes in publications of randomised controlled trials on the treatment of age-related macular degeneration: cross-sectional evaluation Tulka, Sabrina Geis, Berit Baulig, Christine Knippschild, Stephanie Krummenauer, Frank BMJ Open Medical Publishing and Peer Review OBJECTIVE: The aim of this cross-sectional study was to examine the completeness and accuracy of the reporting of sample size calculations in randomised controlled trial (RCT) publications on the treatment of age-related macular degeneration (AMD). METHODS: A sample of 97 RCTs published between 2004 and 2014 was reviewed for the calculation of their sample size. It was examined whether a (complete) description of the sample size calculation was presented. Furthermore, the sample size was recalculated, whenever possible based on the published details, in order to verify the reported number of patients. PRIMARY OUTCOME MEASURE: The primary endpoint of this cross-sectional investigation was a described sample size calculation that was reproducible, complete and correct (maximum tolerated deviation between reported and replicated sample size ±2 participants per trial arm). RESULTS: A total of 50 publications (52%) did not provide any information on the justification of the number of patients included. Only 17 publications (18%) provided all the necessary parameters for recalculation; 8 of 97 (8%, 95%-CI: 4% to 16%) publications achieved the primary endpoint. The median relative deviation between reported and recalculated sample sizes was 1%, with a range from −43% to +66%. CONCLUSION: Although a transparent sample size legitimation is a crucial determinant of an RCT’s methodological validity, more than half of the RCT publications considered failed to report them. Furthermore, reported sample size legitimations were often incomplete or incorrect. In summary, clinical authors should pay more attention to the transparent reporting of sample size calculation, and clinical journal reviewers may opt to reproduce reported sample size calculations. SYNOPSIS: More than half of the analysed RCT publications on the treatment of AMD did not report a transparent sample size calculation. Only 8% reported a complete and correct sample size calculation. BMJ Publishing Group 2019-10-10 /pmc/articles/PMC6797239/ /pubmed/31601589 http://dx.doi.org/10.1136/bmjopen-2019-030312 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Medical Publishing and Peer Review
Tulka, Sabrina
Geis, Berit
Baulig, Christine
Knippschild, Stephanie
Krummenauer, Frank
Validity of sample sizes in publications of randomised controlled trials on the treatment of age-related macular degeneration: cross-sectional evaluation
title Validity of sample sizes in publications of randomised controlled trials on the treatment of age-related macular degeneration: cross-sectional evaluation
title_full Validity of sample sizes in publications of randomised controlled trials on the treatment of age-related macular degeneration: cross-sectional evaluation
title_fullStr Validity of sample sizes in publications of randomised controlled trials on the treatment of age-related macular degeneration: cross-sectional evaluation
title_full_unstemmed Validity of sample sizes in publications of randomised controlled trials on the treatment of age-related macular degeneration: cross-sectional evaluation
title_short Validity of sample sizes in publications of randomised controlled trials on the treatment of age-related macular degeneration: cross-sectional evaluation
title_sort validity of sample sizes in publications of randomised controlled trials on the treatment of age-related macular degeneration: cross-sectional evaluation
topic Medical Publishing and Peer Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797239/
https://www.ncbi.nlm.nih.gov/pubmed/31601589
http://dx.doi.org/10.1136/bmjopen-2019-030312
work_keys_str_mv AT tulkasabrina validityofsamplesizesinpublicationsofrandomisedcontrolledtrialsonthetreatmentofagerelatedmaculardegenerationcrosssectionalevaluation
AT geisberit validityofsamplesizesinpublicationsofrandomisedcontrolledtrialsonthetreatmentofagerelatedmaculardegenerationcrosssectionalevaluation
AT bauligchristine validityofsamplesizesinpublicationsofrandomisedcontrolledtrialsonthetreatmentofagerelatedmaculardegenerationcrosssectionalevaluation
AT knippschildstephanie validityofsamplesizesinpublicationsofrandomisedcontrolledtrialsonthetreatmentofagerelatedmaculardegenerationcrosssectionalevaluation
AT krummenauerfrank validityofsamplesizesinpublicationsofrandomisedcontrolledtrialsonthetreatmentofagerelatedmaculardegenerationcrosssectionalevaluation